Protocol for the Examination of Specimens From Patients With Carcinomas of the Thyroid Gland

Version: 4.3.0.0
Protocol Posting Date: June 2021
CAP Laboratory Accreditation Program Protocol Required Use Date: March 2022

The changes included in this current protocol version affect accreditation requirements. The new deadline for implementing this protocol version is reflected in the above accreditation date.

For accreditation purposes, this protocol should be used for the following procedures AND tumor types:

<table>
<thead>
<tr>
<th>Procedure</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Resection</td>
<td>Includes specimens designated thyroidectomy, lobectomy and partial excision</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Tumor Type</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carcinoma</td>
<td>Includes papillary, follicular, anaplastic, poorly differentiated, and medullary cancers</td>
</tr>
</tbody>
</table>

This protocol is NOT required for accreditation purposes for the following:

<table>
<thead>
<tr>
<th>Procedure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biopsy</td>
</tr>
<tr>
<td>Primary resection specimen with no residual cancer (e.g. following neoadjuvant therapy)</td>
</tr>
<tr>
<td>Cytologic specimens</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Tumor Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>Noninvasive follicular thyroid neoplasm with papillary like nuclear features (NIFTP)</td>
</tr>
<tr>
<td>Thyroid carcinomas arising from struma ovari</td>
</tr>
<tr>
<td>Thyroid carcinomas arising in thyroglossal duct cysts</td>
</tr>
</tbody>
</table>

The following tumor types should NOT be reported using this protocol:

<table>
<thead>
<tr>
<th>Tumor Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lymphoma (consider the Hodgkin or non-Hodgkin Lymphoma protocols)</td>
</tr>
<tr>
<td>Sarcoma (consider the Soft Tissue protocol)</td>
</tr>
</tbody>
</table>

Authors

Ozgur Mete, MD*; Sylvia L. Asa, MD, PhD; Martin J. Bullock, MD; Sally E. Carty, MD; Steven Hodak, MD; Jonathan B. McHugh, MD; Yuri E. Nikiforov, MD, PhD; Jason Pettus, MD; Mary S. Richardson, MD, DDS; Raja R. Seethala, MD; Jatin Shah, MD; Lester D.R. Thompson, MD.

With guidance from the CAP Cancer and CAP Pathology Electronic Reporting Committees.

* Denotes primary author.
Accreditation Requirements
This protocol can be utilized for a variety of procedures and tumor types for clinical care purposes. For accreditation purposes, only the definitive primary cancer resection specimen is required to have the core and conditional data elements reported in a synoptic format.

- **Core data elements** are required in reports to adequately describe appropriate malignancies. For accreditation purposes, essential data elements must be reported in all instances, even if the response is “not applicable” or “cannot be determined.”
- **Conditional data elements** are only required to be reported if applicable as delineated in the protocol. For instance, the total number of lymph nodes examined must be reported, but only if nodes are present in the specimen.
- **Optional data elements** are identified with “+” and although not required for CAP accreditation purposes, may be considered for reporting as determined by local practice standards.

The use of this protocol is not required for recurrent tumors or for metastatic tumors that are resected at a different time than the primary tumor. Use of this protocol is also not required for pathology reviews performed at a second institution (ie, secondary consultation, second opinion, or review of outside case at second institution).

Synoptic Reporting
All core and conditionally required data elements outlined on the surgical case summary from this cancer protocol must be displayed in synoptic report format. Synoptic format is defined as:

- Data element: followed by its answer (response), outline format without the paired Data element: Response format is NOT considered synoptic.
- The data element should be represented in the report as it is listed in the case summary. The response for any data element may be modified from those listed in the case summary, including “Cannot be determined” if appropriate.
- Each diagnostic parameter pair (Data element: Response) is listed on a separate line or in a tabular format to achieve visual separation. The following exceptions are allowed to be listed on one line:
  - Anatomic site or specimen, laterality, and procedure
  - Pathologic Stage Classification (pTNM) elements
  - Negative margins, as long as all negative margins are specifically enumerated where applicable
- The synoptic portion of the report can appear in the diagnosis section of the pathology report, at the end of the report or in a separate section, but all Data element: Responses must be listed together in one location.

Organizations and pathologists may choose to list the required elements in any order, use additional methods in order to enhance or achieve visual separation, or add optional items within the synoptic report. The report may have required elements in a summary format elsewhere in the report IN ADDITION TO but not as replacement for the synoptic report ie, all required elements must be in the synoptic portion of the report in the format defined above.

Summary of Changes

v 4.3.0.0
- General Reformatting
- Revised Clinical Section
- Added Tumor Necrosis Question
- Revised Margins Section
- Revised Lymph Nodes Section
- Added Distant Metastasis Section
- Removed pTX and pNX Staging Classification
**Reporting Template**

Protocol Posting Date: June 2021
Select a single response unless otherwise indicated.

CASE SUMMARY: (THYROID GLAND)
Standard(s): AJCC-UICC 8

CLINICAL (Note A)

+Predisposing Condition(s) (select all that apply)
___ Radiation exposure (specify type): ______________________
___ Family history of thyroid cancer: ______________________
___ Other (specify): __________________

+Preoperative Serum Marker Findings (specify type[s] and result[s]): _________________

+Postoperative Serum Marker Findings (specify type[s] and result[s]): _________________

+Clinical History (specify): _________________

SPECIMEN (Note B)

Procedure
___ Total thyroidectomy
___ Right lobectomy
___ Left lobectomy
# Anything less than a lobectomy, including substernal excision
___ Right partial excision#
___ Left partial excision#
___ Partial excision (specify type, if possible)#: __________________
___ Right lobectomy with isthmusectomy (hemithyroidectomy)
___ Left lobectomy with isthmusectomy (hemithyroidectomy)
___ Right lobe with partial left lobectomy (subtotal or near total thyroidectomy)
___ Left lobe with partial right lobectomy (subtotal or near total thyroidectomy)
___ Completion thyroidectomy (reoperative)
___ Other (specify): __________________
___ Not specified

TUMOR

Tumor Focality (Note C)
___ Unifocal
___ Multifocal
___ Cannot be determined

Tumor Characteristics
For multiple tumors of the same cellular lineage (e.g., multifocal papillary carcinoma, follicular carcinoma, etc.), one may choose to repeat the following 10 elements (Tumor Site, Histologic Type, Tumor Size, Mitotic Rate, Tumor Necrosis, Angioinvasion, Lymphatic Invasion, Perineural Invasion, Extra-thyroidal Extension, and Margin Status) for clinically relevant tumors. For medullary thyroid carcinoma, please use a separate synoptic report.

+Tumor Identifier (for cases with multiple tumors): _________________
Tumor Site (Note C) (select all that apply)
- __ Right lobe
- __ Left lobe
- __ Isthmus
- __ Pyramidal lobe
- __ Other (specify): ___________________
- __ Cannot be determined: ___________________

Tumor Size (Note I)
- __ Greatest dimension in Centimeters (cm): __________________ cm
  **+Additional Dimension in Centimeters (cm): ____ x ____ cm**
- __ Cannot be determined (explain): ___________________

Histologic Type (Notes D,E,F,G,H)

**Papillary Carcinomas**
- __ Papillary carcinoma, classic (usual, conventional)
- __ Papillary carcinoma, follicular variant, encapsulated / well demarcated, with tumor capsular invasion
  # A subset of noninvasive tumors can now be reclassified as NIFTP
- __ Papillary carcinoma, follicular variant, encapsulated / well demarcated, non-invasive#
- __ Papillary carcinoma, tall cell variant
- __ Papillary carcinoma, hobnail variant
- __ Papillary carcinoma, columnar cell variant
- __ Papillary carcinoma, solid / trabecular variant
- __ Papillary carcinoma, cribriform-morular variant
- __ Papillary carcinoma, diffuse sclerosing variant
- __ Papillary carcinoma, other variant (specify): ___________________

**Papillary carcinoma**
  ## This category is not overtly malignant; reporting is optional and only size, laterality, and margin status are reported.
- __ Non-invasive follicular thyroid neoplasm with papillary like nuclear features (NIFTP)##

**Follicular Carcinomas**
- __ Follicular carcinoma, minimally invasive
- __ Follicular carcinoma, encapsulated angioinvasive
- __ Follicular carcinoma, widely invasive
- __ Follicular carcinoma, minimally invasive, other variant (specify): ___________________
- __ Follicular carcinoma, encapsulated angioinvasive, other variant (specify): ___________________
- __ Follicular carcinoma, widely invasive, other variant (specify): ___________________
- __ Follicular carcinoma, NOS

**Oncocytic (Hürthle cell) Carcinomas**
- __ Oncocytic (Hürthle cell) carcinoma, minimally invasive
- __ Oncocytic (Hürthle cell) carcinoma, encapsulated angioinvasive
- __ Oncocytic (Hürthle cell) carcinoma, widely invasive

**Poorly Differentiated Thyroid Carcinoma**
- __ Poorly differentiated thyroid carcinoma

**Anaplastic Carcinomas**
- __ Undifferentiated (anaplastic) carcinoma, focal or minor component without extrathyroidal extension
- __ Undifferentiated (anaplastic) carcinoma, major component
- __ Undifferentiated (anaplastic) carcinoma, NOS

**Medullary Carcinomas**
- __ Medullary carcinoma
- __ Medullary microcarcinoma
- __ Mixed (composite) medullary carcinoma and follicular epithelial-derived carcinoma (specify): ___________________
___ Other histologic type not listed (specify): __________________________
___ Carcinoma, type cannot be determined: __________________________

+Histologic Type Comment: __________________________

+Mitotic Rate
___ Specify mitoses per 2 mm2: __________________________ mitoses per 2 mm2
___ Other (specify): __________________________
___ Cannot be determined

+Tumor Necrosis
___ Not identified
___ Present

Angioinvasion (vascular invasion) (Note K)
___ Not identified
___ Focal (less than 4 vessels)
___ Extensive (4 or more vessels)
___ Present (extent not specified)
___ Cannot be determined: __________________________

Lymphatic Invasion (Note K)
___ Not identified
___ Present
___ Cannot be determined: __________________________

+Perineural Invasion
___ Not identified
___ Present
___ Cannot be determined: __________________________

Extrathyroidal Extension (Note J)
___ Not identified
___ Present, microscopic strap muscle invasion only, with no clinical / macroscopic evidence of invasion
___ Present, clinical / macroscopic AND histologically confirmed
___ Invading only strap muscles (i.e., pT3b)
___ Invading subcutaneous soft tissues, larynx, trachea, esophagus or recurrent laryngeal nerve (i.e., pT4a)
___ Invading prevertebral fascia or encasing the carotid artery or mediastinal vessels (i.e., pT4b)
___ Cannot be determined: __________________________

+Tumor Comment: __________________________

Margin Status (Note L)
___ All margins negative for carcinoma

+Distance from Invasive Carcinoma to Closest Margin

Specify in Millimeters (mm)
___ Exact distance: _________________ mm
___ At least: _________________ mm
___ Less than 1 mm
___ Other (specify):
___ Cannot be determined (explain): __________________________
___ Carcinoma present at margin

Margin(s) Involved by Carcinoma
___ Specify involved margin(s):
___ Cannot be determined (explain): __________________________
___ Other (specify):
___ Cannot be determined (explain): __________________________
REGIONAL LYMPH NODES (Note M)

Regional Lymph Node Status
___ Not applicable (no regional lymph nodes submitted or found)
___ Regional lymph nodes present
    ___ All regional lymph nodes negative for tumor
    ___ Tumor present in regional lymph node(s)

Number of Lymph Nodes with Tumor
___ Exact number (specify): _________________
___ At least (specify): _________________
___ Other (specify): _________________
___ Cannot be determined (explain): _________________

Nodal Level(s) Involved (select all that apply)
___ Level VI - pretracheal, paratracheal and prelaryngeal / Delphian, perithyroidal (central
    compartment dissection)
___ Level VII (superior mediastinal lymph nodes)
___ Right Lateral Level I
___ Right Lateral Level II
___ Right Lateral Level III
___ Right Lateral Level IV
___ Right Lateral Level V
___ Left Lateral Level I
___ Left Lateral Level II
___ Left Lateral Level III
___ Left Lateral Level IV
___ Left Lateral Level V
___ Other (specify): _________________
___ Cannot be determined (explain): _________________

Size of Largest Metastatic Deposit
Specify in Centimeters (cm)
___ Exact size: _________________ cm
___ At least: _________________ cm
___ Other (specify): _________________
___ Cannot be determined (explain): _________________

Extranodal Extension (ENE)
___ Not identified
___ Present
___ Cannot be determined: _________________
___ Other (specify): _________________
___ Cannot be determined (explain): _________________

Number of Lymph Nodes Examined
___ Exact number (specify): _________________
___ At least (specify): _________________
___ Other (specify): _________________
___ Cannot be determined (explain): _________________

Nodal Level(s) Examined (select all that apply)
___ Level VI - pretracheal, paratracheal and prelaryngeal / Delphian, perithyroidal (central
    compartment dissection)
___ Level VII (superior mediastinal lymph nodes)
___ Right Lateral Level I
___ Right Lateral Level II
___ Right Lateral Level III
___ Right Lateral Level IV
___ Right Lateral Level V
___ Left Lateral Level I
___ Left Lateral Level II
___ Left Lateral Level III
___ Left Lateral Level IV
___ Left Lateral Level V
___ Other (specify): _________________
___ Cannot be determined (explain): _________________

+Regional Lymph Node Comment: _________________

DISTANT METASTASIS

Distant Site(s) Involved, if applicable (select all that apply)
___ Not applicable
___ Lung: _________________
___ Bone: _________________
___ Other (specify): _________________
___ Cannot be determined: _________________

PATHOLOGIC STAGE CLASSIFICATION (pTNM, AJCC 8th Edition) (Note N)

Reporting of pT, pN, and (when applicable) pM categories is based on information available to the pathologist at the time the report is issued. As per the AJCC (Chapter 1, 8th Ed.) it is the managing physician’s responsibility to establish the final pathologic stage based upon all pertinent information, including but potentially not limited to this pathology report.

TNM Descriptors (select all that apply)
___ Not applicable
___ m (multiple primary tumors)
___ r (recurrent)
___ y (post-treatment)

pT Category
___ For Papillary, Follicular, Poorly Differentiated, Oncocytic (Hürthle cell) Cell, and Anaplastic Thyroid Carcinoma

   pT Category
   There is no category of carcinoma in situ (pTis) relative to carcinomas of thyroid gland.
   ___ pT not assigned (cannot be determined based on available pathological information)
   ___ pT0: No evidence of primary tumor
   pT1: Tumor size less than or equal to 2 cm in greatest dimension, limited to thyroid
   ___ pT1a: Tumor less than or equal to 1 cm in greatest dimension, limited to the thyroid.
   ___ pT1b: Tumor greater than 1 cm but less than or equal to 2 cm in greatest dimension, limited to the thyroid
   ___ pT1 (subcategory cannot be determined)
   ___ pT2: Tumor greater than 2 cm but less than or equal to 4 cm in greatest dimension, limited to thyroid
pT3: Tumor greater than 4 cm limited to the thyroid, or gross extrathyroidal extension invading only strap muscles
  ___ pT3a: Tumor greater than 4 cm limited to the thyroid
  ___ pT3b: Gross extrathyroidal extension invading only strap muscles (sternohyoid, sternothyroid, thyrohyoid, or omohyoid muscles) from a tumor of any size
  ___ pT3 (subcategory cannot be determined)

pT4: Includes gross extrathyroidal extension beyond the strap muscles
  ___ pT4a: Gross extrathyroidal extension invading subcutaneous soft tissues, larynx, trachea, esophagus, or recurrent laryngeal nerve from a tumor of any size
  ___ pT4b: Gross extrathyroidal extension invading prevertebral fascia or encasing the carotid artery or mediastinal vessels from a tumor of any size
  ___ pT4 (subcategory cannot be determined)

For Medullary Thyroid Carcinoma

pT Category
  ___ pT not assigned (cannot be determined based on available pathological information)
  ___ pT0: No evidence of primary tumor

pT1: Tumor size less than or equal to 2 cm in greatest dimension, limited to thyroid
  ___ pT1a: Tumor less than or equal to 1 cm in greatest dimension, limited to the thyroid.
  ___ pT1b: Tumor greater than 1 cm but less than or equal to 2 cm in greatest dimension, limited to the thyroid
  ___ pT1 (subcategory cannot be determined)

pT2: Tumor greater than 2 cm but less than or equal to 4 cm in greatest dimension, limited to thyroid

pT3: Tumor greater than 4 cm or with extrathyroidal extension
  ___ pT3a: Tumor greater than 4 cm in greatest dimension limited to the thyroid
  ___ pT3b: Tumor of any size with gross extrathyroidal extension invading only strap muscles (sternohyoid, sternothyroid, thyrohyoid or omohyoid muscles)
  ___ pT3 (subcategory cannot be determined)

pT4: Advanced disease
  ___ pT4a: Moderately advanced disease; tumor of any size with gross extrathyroidal extension into the nearby tissues of the neck, including subcutaneous soft tissue, larynx, trachea, esophagus, or recurrent laryngeal nerve
  ___ pT4b: Very advanced disease; tumor of any size with extension toward the spine or into nearby large blood vessels, gross extrathyroidal extension invading the prevertebral fascia, or encasing the carotid artery or mediastinal vessels
  ___ pT4 (subcategory cannot be determined)

pN Category#
# N0b is defined as no radiologic or clinical evidence of locoregional lymph node metastasis
  ___ pN not assigned (no nodes submitted or found)
  ___ pN not assigned (cannot be determined based on available pathological information)

pN0: No evidence of locoregional lymph node metastasis
  ___ pN0a: One or more cytologically or histologically confirmed benign lymph nodes
  ___ pN0 (subcategory cannot be determined)#

pN1: Metastasis to regional nodes
  ___ pN1a: Metastasis to level VI or VII (pretracheal, paratracheal, or prelaryngeal / Delphian, or upper mediastinal) lymph nodes. This can be unilateral or bilateral disease.
  ___ pN1b: Metastasis to unilateral, bilateral, or contralateral lateral neck lymph nodes (levels I, II, III, IV, or V) or retropharyngeal lymph nodes
  ___ pN1 (subcategory cannot be determined)
pM Category (required only if confirmed pathologically)
___ Not applicable - pM cannot be determined from the submitted specimen(s)
___ pM1: Distant metastasis

ADDITIONAL FINDINGS

+Additional Findings (select all that apply)
___ None identified
___ Adenoma
___ Adenomatoid nodule(s) or nodular follicular disease (e.g., nodular hyperplasia, goitrous thyroid)
___ Diffuse hyperplasia (Graves' disease)
___ Thyroiditis (specify type): _________________
___ Parathyroid gland(s) present

+Number of Parathyroid Glands
___ 1
___ 2
___ 3
___ 4
___ Greater than 4 (specify number): _________________

+Location of Parathyroid Gland(s) (select all that apply)
___ Left superior
___ Left inferior
___ Right superior
___ Right inferior
___ Other (specify): _________________

+Parathyroid Gland Findings (select all that apply)
___ Within normal limits
___ Hypercellular
___ Other (specify): _________________
___ C-cell hyperplasia (specify type and focality): _________________
___ Other (specify): _________________

SPECIAL STUDIES
For reporting molecular testing and other cancer biomarker testing results, the CAP Thyroid Biomarker Template should be used.
Pending biomarker studies should be listed in the Comments section of this report.

COMMENTS

Comment(s): _________________
Explanatory Notes

A. Scope of Guidelines
The reporting of thyroid cancer is facilitated by the provision of a case summary illustrating the features required for comprehensive patient care. However, there are many cases in which the individual practicalities of applying such a case summary may not be straightforward. Common examples include finding the prescribed number of lymph nodes, trying to determine the compartments of the radical neck dissection, and determining if isolated tumor cells in a lymph node represent metastatic disease. Case summaries have evolved to include clinical, radiographic, morphologic, immunohistochemical, and molecular results in an effort to guide clinical management. This case summary tries to remain simple while still incorporating important pathologic features as proposed by the American Joint Committee on Cancer (AJCC) Cancer Staging Manual\textsuperscript{1,2} and the World Health Organization Classification of Tumours.\textsuperscript{3} This protocol is to be used as a guide and resource, an adjunct to diagnosing and managing cancers of the thyroid gland in a standardized manner. It should not be used as a substitute for dissection or grossing techniques and does not give histologic parameters to reach the diagnosis. Subjectivity is always a factor, and elements listed are not meant to be arbitrary but are meant to provide uniformity of reporting across all the disciplines that use the information. It is a foundation of practical information that will help to meet the requirements of daily practice to benefit both clinicians and patients alike.

References

B. Anatomical Sites of the Thyroid Gland (Figure 1)
The thyroid gland ordinarily is composed of a right and a left lobe lying adjacent and lateral to the upper trachea and esophagus. An isthmus connects the 2 lobes, and in some cases a pyramidal lobe is present extending cephalad anterior to the thyroid cartilage. Typically, surgical management of thyroid tumors consists of either a lobe with isthmusectomy (sometimes called \textit{hemithyroidectomy}) or total thyroidectomy. Cases with lobectomy followed by completion thyroidectomy in the same operative procedure should be classified as total thyroidectomies. Other procedures include subtotal thyroidectomy and level VI central node dissection.
C. Tumor Site
The thyroid may give rise to multiple foci of carcinoma in the same gland, designated as per AJCC guidelines with the descriptor “(m).” This protocol is applicable to the dominant excised tumor as well as clinically relevant multifocal tumors. The clinically relevant tumors can be defined as tumors that can impart the tumor stage or dictate patient management during the dynamic risk stratification. For multiple tumors of the same cellular lineage (ie. multifocal papillary carcinoma), characteristics of clinically relevant multifocal tumors can be reported in one synoptic report. In multifocal tumors, the pT stage in the synoptic report is based on the worst findings (collectively) of all the tumors of the same cellular lineage. The features of additional foci that do not necessarily alter management can be detailed under the section on Additional Pathologic Findings. For tumors of different cellular lineage (ie. tumor 1 is papillary thyroid carcinoma and tumor 2 is medullary thyroid carcinoma), a second synoptic report should be generated.

D. Histologic Type
The histologic classification recommended below in notes F through H is modified from the World Health Organization (WHO) published recommendations with a few important alterations based on subsequently published studies. This protocol applies only to carcinomas and does not apply to lymphomas, sarcomas, or metastatic tumors to the thyroid gland.

WHO Classification of Carcinoma of the Thyroid
Papillary carcinoma
  Variants (in alphabetical order):
    Classic (usual)
    Clear cell variant
    Columnar cell variant
    Cribriform-morular variant
    Diffuse sclerosing variant
    Follicular variant
    Hobnail variant
    Microcarcinoma (occult, latent, small, microtumor)
    Oncocytic or oxyphilic variant (follicular variant, nonfollicular variant)
    Solid/trabecular variant
    Spindle cell variant
Tall cell variant
Warthin-like variant

Follicular carcinoma
Subtypes:
- Minimally invasive
- Encapsulated angioinvasive
- Widely invasive

Oncocytic (Hürthle cell) carcinoma

Poorly differentiated thyroid carcinomas including insular carcinoma

Medullary carcinoma

Mixed medullary carcinoma and follicular epithelial derived thyroid carcinoma

Undifferentiated (anaplastic) carcinoma
Carcinoma, type cannot be determined

Hürthle cell tumors have their own chapter in the 4th edition of the WHO Classification.

References

E. Histologic Grade
While AJCC includes a generic 4-tiered scheme for thyroid cancers as with other cancers, application of this to the current classification of thyroid cancers is difficult and not particularly relevant, as there is no grading system beyond what is implied by each specific histologic variant.

F. Papillary Carcinoma
Hobnail cell variant of papillary carcinoma is an aggressive variant that is characterized by increased frequency of nodal and distant metastatic disease as well as local recurrence. The cribriform morular variant is a biologically distinct variant characterized by APC or CTNNB1 mutations and shows an association with familial adenomatous polyposis coli, in some cases preceding recognition of colon polyps or other extracolonic manifestations. Diffuse sclerosing variant is a locoregionally aggressive variant with a high rate of nodal metastasis and locoregional recurrence, though overall survival when corrected for other high-risk parameters is not entirely clear. Nonetheless, this variant appears to necessitate more aggressive initial surgical management including extent of node dissection.

Follicular variant of papillary carcinoma is important to document because it has recently been substratified based on outcome into noninvasive (encapsulated/well demarcated) and infiltrative follicular variants. Unencapsulated infiltrative follicular variants have a behavior similar to classic papillary carcinoma, particularly in terms of propensity for nodal metastasis, while the behavior of encapsulated follicular variant is more indolent.

Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features (NIFTP)
A subset of noninvasive follicular variants of papillary thyroid carcinoma is currently classified under the new designation noninvasive follicular thyroid neoplasm with papillary like nuclear features (NIFTP). This shift in nomenclature arose as an effort to encourage conservative management of these lesions given their extremely low risk of structural and chemical recurrence. NIFTP is still not entirely considered benign and remains an actionable surgical disease, albeit with a more conservative approach. As NIFTP is not overtly malignant, it is technically not required to report these under this cancer protocol. However, it is encouraged to report these, though only limited parameters are relevant, namely size, laterality, and margin status.
It must be noted that not all tumors previously designated as noninvasive follicular variant of papillary thyroid carcinoma would qualify as NIFTP. Main inclusion criteria require that the tumor is:
- Encapsulated or well demarcated
- Follicular patterned
- Demonstrating at least focal nuclear features of papillary thyroid carcinoma

Another key requirement for this designation is that the entire lesional border has been submitted for histologic evaluation. However, several exclusionary criteria exist as well in order to ensure that the NIFTP category remains indolent and are as follows:
- Infiltration/tumoral capsular invasion.
- Solid/trabecular or insular growth greater than 30%
- True papillary growth (with fibrovascular cores) (even 1 well-formed papillary structure)
- Psammoma bodies
- Tall cell, hobnail cell, columnar cell, or cribriform morular morphology
- Necrosis
- Mitoses greater than 3 per 10 consecutive high power fields (HPF) (in solid/microfollicular areas)

When a tumor fulfills these inclusion and exclusion criteria, NIFTP designation is appropriate. Of note, NIFTP is not well-validated in oncocytic, sub-centimeter, and multifocal lesions. In these scenarios, the designation NIFTP is not absolutely contraindicated but there are inadequate data to substantiate this designation. It must be emphasized that in order for NIFTP to accurately reflect an indolent tumor type, rigorous application of the inclusion and exclusion criteria should be employed – specifically complete submission of tumor normal interface, adequate sampling of the tumor center (ie, at least 1 section per centimeter of tumor) and strict observation of histologic criteria. NIFTP is still an evolving diagnosis, and certain problematic areas have already been noted. For instance, it is challenging to evaluate for invasion in well-circumscribed unencapsulated tumors. The recommendation for qualification as NIFTP in this scenario is to demonstrate a complete rim of compressed thyroid parenchyma with absolutely no mingling of normal and neoplastic follicles. Another problematic area is recognition of exclusionary papillae. A papilla in this context is well formed, demonstrates a fibrovascular core (unlike the follicles seen in Sanderson’s polster), and shows overt nuclear features of papillary carcinoma. Initial criterion of less than 1% is noted to be subjective and difficult to apply. Additionally, this cut-off was already shown to be inferior to a 0% cut-off in ensuring indolent outcome. Thus even 1 well-formed papilla as defined above should be considered exclusionary.

Other variants that may have prognostic and therapeutic value but are rare and not well validated include:
- Clear cell
- Columnar cell
- Macrofollicular
- Oncocytic or oxyphilic
- Solid/trabecular
- Warthin-like

Papillary microcarcinomas (also historically referred to as papillary microtumor, occult, latent, or small papillary carcinoma) are not technically a specific variant but refer to papillary carcinomas that are found incidentally measuring 1 cm or less. In spite of their rather common identification in thyroid gland resections and apparent indolent biologic behavior, it is the recommendation to issue a protocol for all cases in which papillary thyroid carcinoma is found, including subcentimeter carcinomas, whether incidentally found in a thyroid gland removed for other reasons (eg, multinodular goiter), discovered
clinically (palpable, visible nodule), and/or discovered by imaging. Given the more sophisticated diagnostic (eg, imaging) modalities currently available, small (ie, less than 1 cm) lesions are being identified and resected. In an effort to have these papillary microcarcinomas reported and documented in tumor registries, thereby providing for long-term follow-up and better determination of their biologic nature, it is recommended that they should also be reported following this CAP thyroid protocol. More recently, certain histologic features have been shown to correlate with nodal metastasis in papillary microcarcinomas. A combined histologic-molecular scoring scheme has been proposed for microcarcinomas based on BRAF mutation status, subcapsular location, peri- and intratumoral fibrosis, and multifocality. This is not yet validated, but documentations of the aforementioned morphologic parameters (with or without mutational status) may be useful in management. 

References


G. Follicular Carcinoma

Follicular carcinoma is a well-differentiated carcinoma type defined by invasiveness in the absence of diagnostic nuclear features of papillary thyroid carcinoma. The diagnosis of follicular carcinoma and its distinction from follicular adenoma primarily depends on the identification of invasion of the tumor capsule and/or vascular spaces (see also note I).

A few cytomorphological variants of follicular carcinomas defined in the past include oncocytic (Hürthle cell) variant, clear cell variant, mucinous variant, and follicular carcinoma with signet-ring cells. Historically
oncocytic carcinoma was considered a distinct entity. Even now the debate continues among experts as to whether this tumor is sufficiently biologically distinct as to warrant categorization as a separate entity. This variant is often more aggressive and radioactive iodine resistant. However, when controlled for stage and extent of invasion, this difference is diminished. Nevertheless, oncocytic (Hürthle cell) carcinomas have now their own chapter in the 4th edition of the WHO classification.

The 4th edition of the WHO classification subtyped follicular carcinoma as follows:
- Minimally invasive follicular carcinoma
- Encapsulated angioinvasive follicular carcinoma
- Widely invasive follicular carcinoma

Criteria for Tumor Capsular Invasion
While conceptually simple, there is no consensus as to the definition of the tumor capsular invasion. Some authorities require complete transgression of the capsule, while other authorities do not require complete transgression of the capsule. Figure 2 depicts the various histologic appearances for the presence or absence of capsular invasion. While a number of the illustrated representations of capsular invasion would be accepted by all pathologists (eg, C, D, E, H), other depictions listed as “Not yet” (eg, F, G, I) may be acceptable to some pathologists as representing capsular invasion. The use of multiple levels can assist the diagnosis of the tumor capsular invasion. The impact of previous biopsy may confound the interpretation of capsular invasion and must be considered.

Figure 2. Tumor Capsular invasion (CI). Schematic drawing for the interpretation of the presence or absence of CI. The diagram depicts a follicular neoplasm (orange) surrounded by a fibrous capsule (green). A. Bosselation on the inner aspect of the capsule does not represent CI. B. Sharp tumor bud invades into but not through the capsule suggesting invasion requiring deeper sections to exclude. C. Tumor totally transgresses the capsule invading beyond the outer contour of the capsule qualifying as CI. D. Tumor clothed by thin (probably new) fibrous capsule but already extending beyond an imaginary (dotted) line drawn through the outer contour of the capsule qualifying as CI. E. Satellite tumor nodule with similar features (architecture, cytomorphology) to the main tumor lying outside the capsule qualifying as CI. F. Follicles aligned perpendicular to the capsule suggesting invasion requiring deeper sections to exclude. G. Follicles aligned parallel to the capsule do not represent CI. H. Mushroom-shaped tumor with total transgression of the capsule qualifies as CI. I. Mushroom-shaped tumor within but not through the capsule suggests invasion requiring deeper sections to exclude invasion. J. Neoplastic follicles in the fibrous capsule with a degenerated appearance accompanied by lymphocytes and siderophages does not represent CI but rather capsular rupture related to prior fine-needle aspiration.

The criteria defining minimally invasive follicular carcinoma are controversial. The 4th edition of the WHO classification now separates encapsulated angioinvasive tumors into a distinct more aggressive category than minimally invasive carcinoma. Literature supports this separation. Even 1 focus of angioinvasion places a tumor into this new category. Thus, minimally invasive carcinomas are now restricted to tumoral capsular invasion only.

Widely invasive follicular carcinomas have similarly nebulous definition and consist of those tumors with grossly apparent invasion of thyroid and/or soft tissue (ie, extrathyroidal invasion). The term is usually assigned to tumors with loss of encapsulation and multiple fronts of tumor invasion radiating from the epicenter of the tumor. These tumors are typically accompanied by other markers of aggressiveness such as extrathyroidal extension and extensive vascular invasion.

References

H. Poorly Differentiated and Undifferentiated (Anaplastic) Carcinoma
While the majority of thyroid cancers are well differentiated, a subset are poorly differentiated (historically known as insular, or trabecular, carcinoma) or undifferentiated (anaplastic). These tumor types represent progression to a more aggressive phenotype and are often seen with co-existent or antecedent well-differentiated carcinoma. While detailed histomorphologic review is beyond the scope of this protocol, salient features of both tumor types are listed below.

Briefly, poorly differentiated carcinomas are tumors that display a solid, trabecular, and/or insular growth pattern, and show 1 or more of the following: greater than 3 mitoses per 2mm, necrosis, and nuclear convolution (without other features seen in papillary carcinoma). As noted above, poorly differentiated thyroid carcinoma may be seen as a component of well-differentiated carcinoma, and as little as 10% of a poorly differentiated component is sufficient to confer an aggressive biologic behavior. On the other hand, encapsulated tumors appear to have a more favorable prognosis than unencapsulated tumors, particularly if they show no capsular or vascular invasion with adequate sampling.

Undifferentiated carcinoma represents the most extreme form of tumor progression and consists of a high-grade malignancy with spindled, pleomorphic, squamoid, or even rhabdoid morphology. Undifferentiated carcinoma is almost invariably rapidly lethal. The few exceptions are noteworthy as they mainly consist of well-differentiated tumor with only focal anaplastic transformation. These tumors are treatable surgically and will have a more favorable prognosis than a predominantly anaplastic carcinoma. Thus, tumors with only focal anaplastic areas and no extrathyroidal extension should be delineated from the more common and overtly anaplastic tumors. The maximum percentage of tumor that is allowable by the term focal in this context is unclear at this point, however, and will require judgment on a case-by-case basis.
References


I. Tumor Size

Tumor size has a significant impact on prognosis and is a component of TNM staging. Papillary carcinomas measuring less than 1 cm are associated with an excellent prognosis, while tumors measuring over 4 cm are associated with a worse prognosis. For follicular carcinomas, tumor size over 3.5 cm is associated with a worse prognosis.¹ For medullary carcinomas, size is a staging component, though a recent epidemiologic survey shows that even small tumors (microcarcinomas less than 1.0 cm) have a 20% rate of regional spread and a 5% distant metastatic rate.²

References


J. Extrathyroidal Extension

Extrathyroidal extension refers to involvement of the perithyroidal tissues by a primary thyroid cancer. Since the thyroid gland does not have a well-defined capsule,³ the definition of extrathyroidal extension has been problematic and subjective. On gross examination, the capsule may appear complete, but evidence has shown that microscopically the capsule is focally incomplete or absent in a majority of thyroid glands evaluated at autopsy.² The perithyroidal tissues include sizable blood vessels as well as small peripheral nerves and are continuous with the pretracheal fascia.³ Extension into adipose tissue is a problematic criterion if used alone, given the fact that adipose tissue can be found within the thyroid gland proper under normal conditions and also may be a component of a variety of thyroid lesions including carcinomas.⁴,⁵ Given this state of variability, microscopic extrathyroidal extension that is not grossly evident is no longer a criterion for upstaging. The pT3b stage is now defined by gross extrathyroidal extension into skeletal muscle, which then necessitates review of macroscopic, intraoperative, and radiologic findings. As such, a thorough gross examination and review of the operative and radiologic findings are now essentially required to document the “gross” extrathyroidal extension required to upstage a tumor. Recent evidence also suggests that the identification of microscopic extra-thyroidal extension is associated with reduced disease-free survival irrespective of tumor size.⁶ While other studies are needed to confirm this finding, documentation of microscopic strap muscle invasion may help to assist the dynamic risk stratification of patients with differentiated thyroid carcinoma that have otherwise low risk
disease. However, the identification of microscopic strap muscle invasion should not be used to upstage the tumor as pT3b in the absence of gross or intraoperative evidence of strap muscle invasion.

References

K. Angioinvasion (Vascular Invasion) and Lymphatic Invasion
Angiolympathic invasion is an important parameter for both papillary and follicular carcinomas. Given the preferential spread of papillary carcinoma via lymphatics and follicular carcinoma via hematogenous routes, the vessels invaded by papillary carcinoma are usually lymphatic spaces and those in follicular carcinoma are usually blood vessels. However, papillary carcinomas can involve vascular spaces, as indicated by occasional hematogenous spread. Thus, the distinction between vascular and lymphatic invasion is required in that the former is a predictor of a more aggressive pattern of spread.

Criteria for Angioinvasion
As noted above, papillary thyroid carcinomas tend to spread via lymphatics. In addition to tumor deposits within lymphatic spaces, this form of spread may manifest as psammoma bodies alone within these spaces, which are the equivalent of lymphatic invasion for reporting purposes.

For encapsulated follicular carcinomas, criteria are designed to identify venous vascular invasion, as this is the typical means of spread for these tumors. Vascular invasion can be a diagnostic criterion for follicular carcinoma and appears to correlate with poor outcome. As with capsular invasion, vascular invasion, though conceptually straightforward, is controversial and challenging.

For vascular invasion, the blood vessels should be located outside the tumor, within the capsule, or outside the capsule. The involved spaces should include capsular or extracapsular vessels. While angioinvasion of a venous caliber space is fairly easily recognized, occasionally separating capillary sized vascular spaces from lymphatics may be difficult. Morphologically smaller vascular spaces will still have red blood cells within. In challenging cases, markers selective for vascular and lymphatic endothelium, such as CD31 and podoplanin (D2-40), respectively, may be useful. Figure 3 depicts the various histologic appearances of vascular invasion. The minimal requirements for clinically meaningful vascular invasion are currently a point of controversy. Historically, the presence of endothelialized tumor alone has been the minimal criterion to identify vascular space invasion, a finding supported in the literature. More recently, however, 1 group has raised the caveat that tumor cells within vascular lumina unassociated with thrombus, and tumor cells underlying intact endothelium could represent “pseudoinvasion” given the fenestrated endothelial network of endocrine organs. Using more rigorous criteria, namely invasion of tumor cells through a vessel wall as well as thrombus formation in association with tumor, this group demonstrated that over one-third of tumors that fulfilled these criteria had distant metastases. These rigid criteria are also highly predictive of aggressive disease in medullary thyroid carcinoma.
While these more rigid criteria require validation from additional studies, they set the framework for the minimal criteria for unequivocal and meaningful vascular invasion, to reiterate: invasion of tumor through a vessel wall accompanied by fibrin thrombus. It is acknowledged that the risk of metastasis when these criteria are not fulfilled by a focus in vessels is not entirely absent.\(^5\)

Additionally, some investigators have suggested that the number of foci of vascular invasion has prognostic impact as well.\(^6,7,8\) In some studies, encapsulated follicular carcinoma, oncocytic variant with 4 or more foci of vascular invasion, has a significant recurrence rate (47\%) even if the foci of angioinvasion are microscopic.\(^7\) On the other hand, another study showed that follicular oncocytic (Hürthle cell) carcinomas with a total of 2 foci of capsular/vascular invasion did not recur after a long follow-up.\(^8\) Moreover, in a series of 4000 thyroid carcinomas of follicular epithelial origin, angioinvasive differentiated thyroid carcinomas that developed distant metastases revealed predominantly a single focus of angioinvasion, and there were no more than 2 foci of vascular invasion.\(^2\) Thus, the use of appropriate criteria seems to be more critical than the number of involved vessels.\(^2\)

**Figure 3.** Vascular invasion (VI): Schematic drawing for the interpretation of the presence or absence of significant VI. The diagram depicts a follicular neoplasm (green) surrounded by a fibrous capsule (tan). The driving concepts behind significant VI are penetration through the vessel wall and a reaction to the vascular deposit, namely thrombus formation, which may range from subtle and fibrinoid in nature to large and heavily organized.

A through C represent scenarios where tumor in vessels are not counted as VI. A. Free-floating irregular tumor fragments often result from artifactual displacement. B. Tumor bulging and indenting the vessel wall does not count as VI. C. Endothelialized tumor floating in an intracapsular vessel may result from tangential sectioning of tumor bulging into a vessel, often at a branch or bifurcation. These findings can however prompt deeper levels (at least by 3) to exclude definitive VI (see E through G).

**** D represents a common but contentious scenario among experts, in light of these new proposed criteria for significant VI. This endothelialized tumor deposit is juxtaposed to the vessel wall. As this is somewhat similar to C, and there is no obvious thrombus, technically this would not count as significant VI. One counterargument is that the endothelialized appearance represents “organization” of a tumor thrombus and is thus still significant. While deeper levels may help, this scenario may still be considered a “judgment call” based on current level of evidence.

E through G represent unequivocal VI. E. Tumor is juxtaposed to vessel wall and is associated with a thrombus. F. Tumor penetrating vessel wall also demonstrating thrombus formation at its neck. G. Tumor fragments in intermingled with an organized thrombus and adherent to vessel wall.

*Note: While there is no standard definition of “deeper levels,” generally, each level is at a certain interval (ie, 3 serial sections deeper or 15-micron intervals) below the original H&E rather than an immediate serial section.*

References

L. Margins
By convention, margin status is a required data element in association with thyroid cancers. The “margin” is defined as the surface of the thyroid specimen, usually the outer aspect of the thyroid gland and/or inked edge of the specimen. The evaluation of the relationship of tumor to the inked edge of the tissue represents determination of margin status. It should be noted that the thyroid “capsule” is not an anatomically defined structure. Evidence has shown that microscopically the capsule is focally incomplete or absent in a majority of thyroid glands evaluated at autopsy. Further, unlike hollow organs such as the gastrointestinal tract where there is continuity of the entire viscera such that a real surgical and pathologic margin exists, the same does not hold true for the thyroid gland such that tumor at the margin (ie, capsule and/or ink) does not correlate to incomplete excision. Few published studies have addressed the influence of margin status and patient outcome. Most surgeons, endocrinologists, and nuclear medicine specialists request information on margin status. While this makes intuitive sense, and it is recommended that a positive margin be mentioned in the final pathology report, meticulous studies on the effect of positive margins and outcome in large series of patients with long-term follow-up are lacking. Indeed, there is no data to date on the prognostic value of close margins as an independent or co-variable.

References

M. Lymph Nodes
Regional Lymph Nodes
Regional lymph node spread from thyroid cancer is common but of less prognostic significance in patients with well-differentiated tumors (papillary) than in medullary cancers. The adverse prognostic influence of lymph node metastasis in patients with differentiated carcinomas is observed only in the older age group. In comparison to macrometastatic disease, micrometastases in thyroid cancer of follicular cell differentiation are of even less clinical value. Based on a few studies to date, micrometastasis does not appear to confer an increased risk of locoregional recurrence as compared to node-negative patients and does not likely warrant more aggressive intervention. The same holds true for isolated tumor cells and...
psammomatous calcifications (psammoma bodies) only in lymph nodes. Reporting of “psammoma bodies only” in lymph nodes is not well defined. While indolent, they do indicate capacity for lymphatic spread and are considered pN1a. On the other end of the spectrum, larger size of lymph node metastases can confer a higher risk of locoregional recurrence, and the American Thyroid Association thus advocates reporting of the size of the largest metastatic focus.\(^3\) Currently, there are no validated differentiated thyroid carcinoma specific cut-offs for size on for macro- or micrometastases.\(^1,5\) However, several experts and the American Thyroid Association adopted the cut-off of 2 mm to define micrometastasis.\(^6\)

**Classification of Neck Dissection**

1. Radical neck dissection
2. Modified radical neck dissection, internal jugular vein and/or sternocleidomastoid muscle spared
3. Selective neck dissection (SND), as specified by the surgeon, with levels and sublevels designated (see Figure 3)\(^7,8\) such as:
   a. Supraomohyoid neck dissection
   b. Posterolateral neck dissection
   c. Lateral neck dissection
   d. Central compartment neck dissection
4. Superselective neck dissection, as specific by the surgeon
5. Extended radical neck dissection, as specified by the surgeon

The first echelon of nodal metastasis consists of the paralaryngeal, paratracheal, and prelaryngeal (Delphian) nodes adjacent to the thyroid gland in the central compartment of the neck, generally described as level VI.\(^3\) Metastases secondarily involve the mid- and lower jugular, the supraclavicular, and (much less commonly) the upper deep jugular and spinal accessory lymph nodes.\(^1\) Lymph node metastasis to submandibular and submental lymph nodes is very rare. Upper mediastinal (level VII) nodal spread occurs frequently both anteriorly and posteriorly. Retropharyngeal nodal metastasis may be seen, usually in the presence of extensive lateral cervical metastasis.\(^1\) Bilateral nodal spread is common. The components of the N category are described as follows: first echelon (perithyroidal/central compartment/level VI and/or superior mediastinal/level VII), or N1a; and lateral cervical/level I-V, or N1b. Commonly utilized surgical techniques for compartmental dissection often result in varying portions of the central compartment being resected en bloc with the thyroidectomy specimen, thus “perithyroidal” lymph nodes seen here are counted towards the N status of the patient (in addition to other parts formally labeled as central compartment or level VI).\(^9\) The lymph node metastasis should also be described according to the level of the neck that is involved. In comparison to metastatic head and neck squamous cell carcinoma, the risk for increased locoregional disease and distant metastasis in the presence of extranodal extension of thyroid cancer is not as widely validated, although several studies have shown an increase risk for distant metastases and death in the presence of extranodal extension.\(^4,10,11\) Therefore, as a recommendation, the pathologist should comment on the presence or absence of extranodal extension. Nodal metastases from medullary thyroid cancer carry a much more ominous prognosis, although they follow a similar pattern of spread.
For purposes of pathologic evaluation, lymph nodes are organized by levels as shown in Figure 4.12

**Figure 4.** The 6 sublevels of the neck for describing the location of lymph nodes within levels I, II, and V. Level IA, submental group; level IB, submandibular group; level IIA, upper jugular nodes along the carotid sheath, including the subdigastric group; level IIB, upper jugular nodes in the submuscular recess; level VA, spinal accessory nodes; and level VB, the supraclavicular and transverse cervical nodes.


In order for pathologists to properly identify these nodes, they must be familiar with the terminology of the regional lymph node groups and with the relationships of those groups to the regional anatomy. Which lymph node groups surgeons submit for histopathologic evaluation depends on the type of neck dissection they perform. Therefore, surgeons must supply information on the types of neck dissections that they perform and on the details of the local anatomy in the specimens they submit for examination, or in other ways orient those specimens for pathologists.7,8

If it is not possible to assess the levels of lymph nodes (for instance, when the anatomic landmarks in the excised specimens are not specified), then the lymph node levels may be estimated as follows: level II, upper third of internal jugular (IJ) vein or neck specimen; level III, middle third of IJ vein or neck specimen; level IV, lower third of IJ vein or neck specimen, all anterior to the sternocleidomastoid muscle.

**Level I. Submental Group (Sublevel IA)**
Lymph nodes within the triangular boundary of the anterior belly of the digastric muscles and the hyoid bone.

**Submandibular Group (Sublevel IB)**
Lymph nodes within the boundaries of the anterior and posterior bellies of the digastric muscle and the body of the mandible. The submandibular gland is included in the specimen when the lymph nodes within this triangle are removed.

**Level II. Upper Jugular Group (Sublevels IIA and IIB)**
Lymph nodes located around the upper third of the internal jugular vein and adjacent spinal accessory nerve extending from the level of the carotid bifurcation (surgical landmark) or hyoid bone (clinical landmark) to the skull base. The posterior boundary is the posterior border of the sternocleidomastoid muscle, and the anterior boundary is the lateral border of the sternohyoid muscle.

**Level III. Middle Jugular Group**
Lymph nodes located around the middle third of the internal jugular vein extending from the carotid bifurcation superiorly to the omohyoid muscle (surgical landmark), or cricothyroid notch (clinical landmark)
inferiorly. The posterior boundary is the posterior border of the sternocleidomastoid muscle, and the anterior boundary is the lateral border of the sternohyoid muscle.

**Level IV. Lower Jugular Group**
Lymph nodes located around the lower third of the internal jugular vein extending from the omohyoid muscle superiorly to the clavicle inferiorly. The posterior boundary is the posterior border of the sternocleidomastoid muscle, and the anterior boundary is the lateral border of the sternohyoid muscle.

**Level V. Posterior Triangle Group (Sublevels VA and VB)**
This group comprises predominantly the lymph nodes located along the lower half of the spinal accessory nerve and the transverse cervical artery. The supraclavicular nodes are also included in this group. The posterior boundary of the posterior triangle is the anterior border of the trapezius muscle, the anterior boundary of the posterior triangle is the posterior border of the sternocleidomastoid muscle, and the inferior boundary of the posterior triangle is the clavicle.

**Level VI. Anterior (Central) Compartment**
Lymph nodes in this compartment include the pre- and paratracheal nodes, precricoid (Delphian) node, and the perithyroidal nodes, including the lymph nodes along the recurrent laryngeal nerve. The superior boundary is the hyoid bone, the inferior boundary is the suprasternal notch, the lateral boundaries are the common carotid arteries, and the posterior boundary by the prevertebral fascia.

**Level VII. Superior Mediastinal Lymph Nodes**
Metastases at level VII are considered regional lymph node metastases; all other mediastinal lymph node metastases are considered distant metastases.

Lymph node groups removed from areas not included in the above levels, eg, scalene, suboccipital, and retropharyngeal, should be identified and reported from all levels separately. Midline nodes are considered ipsilateral nodes.

**Lymph Node Number**
Histologic examination of a selective neck dissection specimen will ordinarily include 6 or more lymph nodes. Histologic examination of a radical or modified radical neck dissection specimen will ordinarily include 10 or more lymph nodes in the untreated neck.1

**Special Procedures for Lymph Nodes**
At the current time, no additional special techniques should be used other than routine histology for the assessment of nodal metastases (ie, sentinel lymph node-type protocols are not advocated). However, confirmation by immunohistochemical staining, including TTF-1, PAX8, and thyroglobulin for papillary carcinoma, calcitonin and monoclonal CEA along with neuroendocrine markers (eg, chromogranins, synaptophysin) for medullary carcinoma, may be required.

References
4. Randolph GW, Duh QY, Heller KS, et al. The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension. Thyroid. 2012;22(11):1144-1152.


N. TNM and Stage Groupings
According to the American Joint Committee on Cancer (AJCC), the TNM stage groupings for papillary and follicular carcinomas and variants thereof are stratified by age, including patients under 55 years of age and patients 55 years and older, as well as the individual TNM parameters. Age is not used to stratify medullary thyroid carcinoma into stage groups.

Undifferentiated (anaplastic) carcinoma is always assigned stage IV and subgrouped into IVA, IVB, IVC by TNM parameters.

All categories may be subdivided: (a) solitary tumor, (b) multifocal tumor. With multifocal tumors, the most aggressive (typically the largest) one is used for classification. The multifocal designation may be used for tumors of different histologies (i.e., a follicular and papillary carcinoma, not just multiple papillary carcinomas). The lymph nodes must be specifically identified to classify regional node involvement.

TNM Descriptors
For identification of special cases of TNM or pTNM classifications, the "m" suffix and "y," "r," and "a" prefixes are used. Although they do not affect the stage grouping, they indicate cases needing separate analysis.

The "m" suffix indicates the presence of multiple primary tumors in a single site and is recorded in parentheses: pT(m)NM.

The "y" prefix indicates those cases in which classification is performed during or following initial multimodality therapy (i.e., neoadjuvant chemotherapy, radiation therapy, or both chemotherapy and radiation therapy). The cTNM or pTNM category is identified by a "y" prefix. The ycTNM or ypTNM
categorizes the extent of tumor actually present at the time of that examination. The “y” categorization is not an estimate of tumor prior to multimodality therapy (ie, before initiation of neoadjuvant therapy).

The “r” prefix indicates a recurrent tumor when staged after a documented disease-free interval, and is identified by the “r” prefix: rTNM.

The “a” prefix designates the stage determined at autopsy: aTNM.

References